Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01798979 · ClinicalTrials.gov registry record · Phase 1

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

A Phase 1 study of Healthy, sponsored by Galapagos.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01798979: Completed Phase 1 study of Healthy, sponsored by Galapagos.

NCT01798979 is a Phase 1 study of Healthy that has completed, run by Galapagos. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01798979, a Phase 1 study of Healthy, has completed, sponsored by Galapagos.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of GLPG0634 on the single dose pharmacokinetic profile of midazolam administered in fasted normal healthy males. Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions: on Day 1, before dosing with GLPG0634 and on Day 8, after multiple oral doses of GLPG0634 (daily for 7 days). Also, the safety and tolerability of multiple oral doses of GLPG0634 co-administered with midazolam in healthy male subjects will be evaluated.

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG GLPG0634

Study Locations (1)

Wisconsin

  • Covance Clinical Research Unit - Madison

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-02
Est. Completion 2013-04
Phase Phase 1

Sponsor

Galapagos

7 total trials

What the Registry Record Tells You About NCT01798979

The ClinicalTrials.gov registry entry for NCT01798979 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT01798979 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01798979 about?

NCT01798979 is a clinical study titled "A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects". This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of GLPG0634 on the single dose pharmacokinetic profile of midazolam administered in fasted normal healthy males. Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions: on Day 1, before ...

What is the current status of trial NCT01798979?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-02. Estimated completion is 2013-04.

What conditions does trial NCT01798979 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01798979?

The interventions under investigation include: Midazolam (DRUG), GLPG0634 (DRUG).

Who is sponsoring clinical trial NCT01798979?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01798979 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.